# Quest Diagnostics (DGX) Stock Analysis: A Robust Healthcare Player with a 4.44% Potential Upside

- Link: https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-a-robust-healthcare-player-with-a-4-44-potential-upside/4121195591
- Published: 2025-05-07T10:16:20+01:00
- Author: Madison Wilson

Quest Diagnostics Incorporated (DGX), a stalwart in the U.S. healthcare sector, 
stands as a key player in the Diagnostics & Research industry. With a market capitalization
of approximately $19.66 billion, the company offers a comprehensive suite of diagnostic
testing and services, extending its reach both domestically and internationally.
From routine testing to advanced clinical diagnostics, Quest Diagnostics serves 
a diverse clientele, including physicians, hospitals, and insurance companies, under
well-known brands like AmeriPath and Dermpath Diagnostics.

Currently trading at $176.11, Quest Diagnostics has experienced a narrow price change
of -0.01% recently. The stock’s 52-week range of $136.14 to $178.50 indicates a 
resilient upward trajectory over the year. Encouragingly, analysts have set a target
price range between $158.69 and $200.00, with an average target price of $183.92,
suggesting a potential upside of 4.44% from its current price level.

Valuation metrics present a mixed picture. While the trailing P/E ratio is not available,
the forward P/E ratio stands at a reasonable 16.72, reflecting investor confidence
in future earnings growth. The company’s earnings per share (EPS) of 7.91 further
underscores its profitability, complemented by a commendable return on equity of
13.95%.

Quest Diagnostics’ financial health is further fortified by robust revenue growth
of 12.10% and a free cash flow of $817.6 million. These figures highlight the company’s
strong operational performance and its ability to generate cash, which is crucial
for funding future growth initiatives and ensuring dividend payouts.

Speaking of dividends, Quest Diagnostics offers a dividend yield of 1.82% with a
payout ratio of 48.04%. This makes it an attractive option for income-focused investors
looking for reliable dividend income from a stable player in the healthcare sector.

Analyst sentiment towards Quest Diagnostics is predominantly positive, with 9 buy
ratings and 10 hold ratings, and notably, no sell ratings. This consensus reflects
a broad consensus of confidence among analysts regarding the company’s performance
and future prospects.

From a technical analysis standpoint, Quest Diagnostics is positioned above its 
50-day moving average of $170.25 and its 200-day moving average of $158.86, suggesting
a bullish trend. The Relative Strength Index (RSI) of 54.89 and a MACD of 2.84 further
support the view of a stable momentum, indicating that the stock is neither overbought
nor oversold.

Founded in 1967 and headquartered in Secaucus, New Jersey, Quest Diagnostics has
built a solid foundation in the healthcare diagnostics arena. Its strategic expansion
into information technology solutions for healthcare organizations and risk assessment
services for the life insurance industry demonstrates its adaptability and forward-
thinking approach.

For individual investors seeking exposure to the healthcare sector, Quest Diagnostics
offers a compelling proposition with its strong market position, consistent revenue
growth, and stable dividend yield. While the potential upside of 4.44% might not
appear substantial, the company’s robust fundamentals and strategic initiatives 
provide a reliable investment opportunity in an ever-evolving market landscape.

Share on:
